Lipid/Metabolic
Hormone therapy associated with MI in male-to-female transsexuals
3 COMMENT S - May 14, 2013 14:00 EDT
Hormone therapy given to transsexuals during gender reassignment appears to be associated with a greater likelihood of cardiovascular disease in men who subsequently become women.

Copenhagen, Denmark - New data from a large gender-identity unit have shown that hormone therapy taken by transsexuals is associated with a higher cardiovascular mortality rate among transsexual women (male to female [M2F]) but not men (female to male [F2M]) [1]. Both, however, had a higher incidence of type 2 diabetes than the general population.

"Our main finding concerning hormonal therapy in transsexual persons is that hormonal therapy seems to be safe in transsexual men in the short and middle term (around eight years)," Dr Katrien Wierckx (University Hospital, Ghent, Belgium) said in an interview.
Read full article »

Acute Coronary Syndromes
SCAAR: Could cheap heparin replace pricy bivalirudin in PCI for non-STE-ACS?
May 21, 2013 13:50 EDT

Arrhythmia/EP
Cardiac-arrest survival highest at hospitals with the fewest
May 21, 2013 11:30 EDT

Clinical cardiology
Inhaled long-acting bronchodilators in COPD flagged again for CV hazard
May 20, 2013 16:00 EDT

Lipid/Metabolic
Dietary saturated fat has undeserved bad reputation, says review
May 17, 2013 16:45 EDT

Interventional/Surgery
High-volume gets demoted in new PCI-competence document
May 9, 2013 11:30 EDT

Heart failure
Dick Cheney: "Coronary artery disease is just a part of who I am"
May 8, 2013 10:40 EDT

Editorial programs
Debate and dialogue between top cardiovascular specialists, produced by
theheart.org's editorial team
View all »
Healthcare reform and cardiology: An even-keeled update
Healthcare reform and cardiology: An even-keeled update
May 2, 2013 08:45 EDT
Breaking embargo: PREVAIL and how we publish data from clinical trials
Breaking embargo: PREVAIL and how we publish data from clinical trials
Apr 12, 2013 16:33 EDT
ACC 2013 research highlights: A slideshow presentation
ACC 2013 research highlights: A slideshow presentation
4 COMMENTS - Mar 19, 2013 10:00 EDT
View all »Collections
heartwire collections groups our most compelling cardiology news coverage and editorial content by popular themes. Find everything on a single topic, in one place, with one click.
Antiplatelet up-and-comers
The quest for ever-more effective drugs to decrease platelet aggregation and reduce the...
Erectile dysfunction and CHD
Years ago, Viagra made the unexpected transition from hypertension and angina drug...
Aspirin and primary prevention
Long considered an essential agent for primary cardiovascular disease prevention...
Dabigatran: A chronology
The presentation of the RE-LY results at the 2009 ESC meeting, showing that dabigatran...
Drugs, money, and glory: Is cancer beating cardiovascular disease?
Heart disease still tops the charts as the number-one killer in most developed...
Related themes
View all »
Other programs
CV & GI Risk
The satellite programs of the CV & GI Risk section are accredited by Medscape. The steering committee members are active in overseeing the development and direction of this educational series.
The Heart of a Woman
Resource Center (view all)